Contrast-enhanced mammography-guided biopsy: technique and initial outcomes.

ABSTRACT: Contrast-enhanced mammography-guided biopsy (CEM-Bx), a novel technique for diagnosing suspicious enhanced lesions, was commercialized for clinical application in 2021; however, there are only a few publications documenting this technique in the existing literature. The aim of this study was to evaluate the procedural performance and preliminary outcomes of CEM-Bx performed in our hospital between from September 2021 to June 2022. We reviewed data of 12 women who underwent CEM-Bx during the study period, including their demographic and procedural characteristics, biopsy success rate, histopathological diagnosis, and average glandular dose (AGD). All women (mean age ± standard deviation: 54±6 years) showed enhanced breast lesions on CEM and underwent CEM-Bx within one week. The success rate

SUBMITTER: Tang YC 

PROVIDER: S-EPMC10423379 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature